This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furuhashi, M. Articles by Östman, A. Search for Related Content PubMed PubMed Citation Articles by Furuhashi, M. Articles by Östman, A.

Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate

¹ Ludwig Institute for Cancer Research, Uppsala Branch, Uppsala, Sweden; ² Department of Medical Biochemistry, University of Göteborg, Göteborg, Sweden; and ³ Ludwig Institute for Cancer Research, Stockholm Branch, Stockholm, Sweden

Platelet-derived growth factor (PDGF) receptor signaling participates in different processes in solid tumors, including autocrine stimulation of tumor cell growth, recruitment of tumor stroma fibroblasts, and stimulation of tumor angiogenesis. In the present study, the B16 mouse melanoma tumor model was used to investigate the functional consequences of paracrine PDGF stimulation of host-derived cells. Production of PDGF-BB or PDGF-DD by tumor cells was associated with an increased tumor growth rate. Characterization of tumors revealed an increase in pericyte abundance in tumors derived from B16 cells producing PDGF-BB or PDGF-DD. The increased tumor growth rate associated with PDGF-DD production was not seen in mice expressing an attenuated PDGF ß-receptor and was thus dependent on host PDGF ß-receptor signaling. The increased pericyte abundance was not associated with an increased tumor vessel density. However, tumor cell apoptosis, but not proliferation, was reduced in tumors displaying PDGF-induced increased pericyte coverage. Our findings thus demonstrate that paracrine PDGF production stimulates pericyte recruitment to tumor vessels and suggest that pericyte abundance influences tumor cell apoptosis and tumor growth.

This article has been cited by other articles:

				W. Lederle, N. Linde, J. Heusel, J. Bzyl, E. C. Woenne, S. Zwick, M. Skobe, F. Kiessling, N. E. Fusenig, and M. M. Mueller Platelet-Derived Growth Factor-B Normalizes Micromorphology and Vessel Function in Vascular Endothelial Growth Factor-A-Induced Squamous Cell Carcinomas Am. J. Pathol., February 1, 2010; 176(2): 981 - 994. [Abstract] [Full Text] [PDF]

				N. Song, Y. Huang, H. Shi, S. Yuan, Y. Ding, X. Song, Y. Fu, and Y. Luo Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1{alpha}/CXCR4 Axis Cancer Res., August 1, 2009; 69(15): 6057 - 6064. [Abstract] [Full Text] [PDF]

				J. Paulsson, T. Sjoblom, P. Micke, F. Ponten, G. Landberg, C.-H. Heldin, J. Bergh, D. J. Brennan, K. Jirstrom, and A. Ostman Prognostic Significance of Stromal Platelet-Derived Growth Factor {beta}-Receptor Expression in Human Breast Cancer Am. J. Pathol., July 1, 2009; 175(1): 334 - 341. [Abstract] [Full Text] [PDF]

				C. Anderberg, H. Li, L. Fredriksson, J. Andrae, C. Betsholtz, X. Li, U. Eriksson, and K. Pietras Paracrine Signaling by Platelet-Derived Growth Factor-CC Promotes Tumor Growth by Recruitment of Cancer-Associated Fibroblasts Cancer Res., January 1, 2009; 69(1): 369 - 378. [Abstract] [Full Text] [PDF]

				D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Sathornsumetee, J. N. Rich, J. A. Quinn, T. F. Lagattuta, M. J. Egorin, S. Gururangan, R. McLendon, et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma Neuro Oncology, June 1, 2008; 10(3): 330 - 340. [Abstract] [Full Text] [PDF]

				J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes & Dev., May 15, 2008; 22(10): 1276 - 1312. [Abstract] [Full Text] [PDF]

				A. F. Muro, F. A. Moretti, B. B. Moore, M. Yan, R. G. Atrasz, C. A. Wilke, K. R. Flaherty, F. J. Martinez, J. L. Tsui, D. Sheppard, et al. An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 638 - 645. [Abstract] [Full Text] [PDF]

				B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]

				J. Mashiah, Y. Wohl, Y. Barnea, S. Schneebaum, A. Gat, F. Misonzhnik-Bedny, and S. Brenner Immunohistochemical Expression of Platelet Growth Factor and Vascular Endothelial Growth Factor in Patients With Melanoma With and Without Redness (Brenner Sign) Arch Dermatol, August 1, 2007; 143(8): 1001 - 1004. [Abstract] [Full Text] [PDF]

				Y. Kitadai, T. Sasaki, T. Kuwai, T. Nakamura, C. D. Bucana, and I. J. Fidler Targeting the Expression of Platelet-Derived Growth Factor Receptor by Reactive Stroma Inhibits Growth and Metastasis of Human Colon Carcinoma Am. J. Pathol., December 1, 2006; 169(6): 2054 - 2065. [Abstract] [Full Text] [PDF]

				K. Kappert, J. Sparwel, A. Sandin, A. Seiler, U. Siebolts, O. Leppanen, S. Rosenkranz, and A. Ostman Antioxidants Relieve Phosphatase Inhibition and Reduce PDGF Signaling in Cultured VSMCs and in Restenosis Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2644 - 2651. [Abstract] [Full Text] [PDF]

				R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes Biology of Platelet-Derived Growth Factor and Its Involvement in Disease Mayo Clin. Proc., September 1, 2006; 81(9): 1241 - 1257. [Abstract] [Full Text] [PDF]

				C. Bondjers, L. He, M. Takemoto, J. Norlin, N. Asker, M. Hellstrom, P. Lindahl, and C. Betsholtz Microarray analysis of blood microvessels from PDGF-B and PDGF-R{beta} mutant mice identifies novel markers for brain pericytes FASEB J, August 1, 2006; 20(10): 1703 - 1705. [Abstract] [Full Text] [PDF]

				M. B. Atkins, D. E. Elder, R. Essner, K. T. Flaherty, T. F. Gajewski, F. G. Haluska, P. Hwu, U. Keilholz, J. M. Kirkwood, J. W. Mier, et al. Innovations and challenges in melanoma: summary statement from the first cambridge conference. Clin. Cancer Res., April 1, 2006; 12(7): 2291s - 2296s. [Abstract] [Full Text] [PDF]

				K. T. Flaherty Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2366s - 2370s. [Abstract] [Full Text] [PDF]

				M. Y. Liu, M. Eyries, C. Zhang, F. S. Santiago, and L. M. Khachigian Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1 Blood, March 15, 2006; 107(6): 2322 - 2329. [Abstract] [Full Text] [PDF]

				L. Xu, R. Tong, D. M. Cochran, and R. K. Jain Blocking Platelet-Derived Growth Factor-D/Platelet-Derived Growth Factor Receptor {beta} Signaling Inhibits Human Renal Cell Carcinoma Progression in an Orthotopic Mouse Model Cancer Res., July 1, 2005; 65(13): 5711 - 5719. [Abstract] [Full Text] [PDF]

				K. Pietras and D. Hanahan A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer J. Clin. Oncol., February 10, 2005; 23(5): 939 - 952. [Abstract] [Full Text] [PDF]